表紙
市場調查報告書

肽治療藥的全球市場:2019年∼2023年

Global Peptide Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317311
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
肽治療藥的全球市場:2019年∼2023年 Global Peptide Therapeutics Market 2019-2023
出版日期: 2018年12月24日內容資訊: 英文 118 Pages
簡介

全球肽治療藥市場,由於癌症、糖尿病、肥胖、心血管疾病等的慢性疾病的增加等而成長。肽對這些疾病的治療表現高效果。該市場預測至2023年將以9%的年複合成長率 (CAGR) 擴大。

本報告提供全球肽治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的供應商簡介等相關資訊彙整。

第1章 摘要整理

第2章 報告的範圍

第3章 市場情況

  • 市場生態系統
  • 市場特長
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模:2018年
  • 市場規模與預測:2018∼2023年

第5章 波特的五力分析

第6章 各給藥途徑市場區隔

  • 市場區隔
  • 比較
  • 非口服
  • 口服
  • 其他
  • 市場機會

第7章 各適應症市場區隔

第8章 各技術市場區隔

第9章 客戶趨勢

第10章 各地區趨勢

  • 各地區市場區隔
  • 比較
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 主要國家
  • 市場機會

第11章 促進要素與課題

第12章 市場趨勢

第13章 供應商環境

第14章 供應商分析

  • 被網羅的供應商
  • 供應商分類
  • 市場定位
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • 武田藥品工業株式會社
  • Teva Pharmaceutical

第15章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR30538

About this market

One of the major drivers of the global peptide therapeutics market is the growing cases of chronic diseases such as cancer, diabetes, obesity, and various cardiovascular diseases. Peptides are known to have high efficacy in the treatment of these diseases. Hence the use of peptides has increased significantly in recent years with the growing prevalence of chronic conditions. The high prevalence of chronic conditions leads to significant demand for curative drugs such as peptides thereby driving market growth. Moreover, the significant need for the treatment of these diseases has led various pharmaceutical companies to develop therapies, including peptide-based drugs. Technavio's analysts have predicted that the peptide therapeutics market will register a CAGR of almost 9% by 2023.

Market Overview

Novel drug delivery

Currently the treatment of various diseases with peptides is predominantly done by administering drugs through the parenteral route. The parenteral RoA is considered to be one of the most undesirable routes for patients due to the invasive nature of the drug administration. Hence. vendors are focusing on developing better drug delivery systems. The increasing need for novel drug delivery systems has led to the development of self-injectable pens by various vendors.

Stringent regulatory policies

One of the major challenges faced by the global peptide therapeutics market is the stringent policies set by regulatory bodies globally. The policies set for the approval of biologic drugs by regulatory bodies are more stringent than for small molecules, which makes it difficult for pharmaceutical companies to launch these drugs in the market. The late launch of drugs or FDA refusal of a drug can hinder the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the peptide therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: MARKET SEGMENTATION BY INDICATION

PART 08: MARKET SEGMENTATION BY TECHNOLOGY

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: RoA - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by RoA
  • Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by RoA
  • Exhibit 27: Market share by 2018-2023 (%)
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Eli Lilly - Vendor overview
  • Exhibit 47: Eli Lilly - Business segments
  • Exhibit 48: Eli Lilly - Organizational developments
  • Exhibit 49: Eli Lilly - Geographic focus
  • Exhibit 50: Eli Lilly - Segment focus
  • Exhibit 51: Eli Lilly - Key offerings
  • Exhibit 52: Eli Lilly - Key customers
  • Exhibit 53: Novo Nordisk - Vendor overview
  • Exhibit 54: Novo Nordisk - Business segments
  • Exhibit 55: Novo Nordisk - Organizational developments
  • Exhibit 56: Novo Nordisk - Geographic focus
  • Exhibit 57: Novo Nordisk - Segment focus
  • Exhibit 58: Novo Nordisk - Key offerings
  • Exhibit 59: Novo Nordisk - Key customers
  • Exhibit 60: Sanofi - Vendor overview
  • Exhibit 61: Sanofi - Business segments
  • Exhibit 62: Sanofi - Organizational developments
  • Exhibit 63: Sanofi - Geographic focus
  • Exhibit 64: Sanofi - Segment focus
  • Exhibit 65: Sanofi - Key offerings
  • Exhibit 66: Sanofi - Key customers
  • Exhibit 67: Takeda Pharmaceutical - Vendor overview
  • Exhibit 68: Takeda Pharmaceutical - Business segments
  • Exhibit 69: Takeda Pharmaceutical - Organizational developments
  • Exhibit 70: Takeda Pharmaceutical - Geographic focus
  • Exhibit 71: Takeda Pharmaceutical - Key offerings
  • Exhibit 72: Takeda Pharmaceutical - Key customers
  • Exhibit 73: Teva Pharmaceutical - Vendor overview
  • Exhibit 74: Teva Pharmaceutical - Business segments
  • Exhibit 75: Teva Pharmaceutical - Organizational developments
  • Exhibit 76: Teva Pharmaceutical - Geographic focus
  • Exhibit 77: Teva Pharmaceutical - Segment focus
  • Exhibit 78: Teva Pharmaceutical - Key offerings
  • Exhibit 79: Teva Pharmaceutical - Key customers
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: List of abbreviations
Back to Top